Núria Ripoll
In recent years there have been great advances both in the diagnosis and treatment of Systemic Autoimmune Diseases (ASD). In this sense, the criteria that define each pathology have been established with greater precision and techniques have been incorporated into care practice that make it possible to calibrate with great precision the location and intensity of inflammatory phenomena. Likewise, the available treatments have increased, which have contributed to relevant changes in the therapeutic strategies to be applied.
All this means that rheumatology specialists need to be in continuous training to optimally address these diseases. "The diagnosis and treatment of SAD in current clinical practice is a real challenge, which is why the Spanish Society of Rheumatology, in collaboration with the Rey Juan Carlos University, has launched this new qualification that will allow students to delve into the clinical management of EAS, as well as providing them with the basic concepts of biomedical research”, said Dr. Sagrario Bustabad, president of the SER, during the signing of the Master's Degree at the Rectorate of the URJC.
The call for the 'SER Master in Systemic Autoimmune Diseases', which has the collaboration of AstraZeneca, has been very well received among rheumatologists. "Thanks to an exclusive program, of a hybrid modality and at the forefront in this area of Rheumatology, specialists will be able to increase and update their training on the etiopathogenesis, diagnosis and treatment of patients with systemic autoimmune diseases", has indicated the Dr. Joan Miquel Nolla, head of the Rheumatology service at the Bellvitge University Hospital and academic director of the Master's agreement together with Dr. Carlos Goicoechea, professor at the URJC.
Dr. Nolla has also pointed out that "the Master has a markedly innovative component, oriented towards the acquisition of expert knowledge through a dynamic methodology in which the students, who already have the important background provided by the specialty, actively participates in the teaching-learning process.
Likewise, AstraZeneca has highlighted the value of the collaboration with the Spanish Society of Rheumatology and the Rey Juan Carlos University in the implementation of this 'SER Master of Systemic Autoimmune Diseases'.
“At AstraZeneca we will continue to contribute our knowledge in the field of medical training and we will continue to promote programs such as this master's degree that provide health professionals with a wide range of up-to-date knowledge of systemic autoimmune diseases. This master's degree is a commitment to multidisciplinary work in which all the key agents involved in the study and approach to EAS, such as Systemic Lupus Erythematosus, combine their contributions to continue advancing in research and updating scientific evidence." highlights Ana Pérez, Medical Director and Regulatory Affairs of AstraZeneca.
For his part, Carlos Goicoechea, Dean of the Faculty of Health Sciences of the URJC, has pointed out that participation in postgraduate activities is one of the highest priorities of his faculty and that "the continuous training of health professionals must be an obligation for universities since health is a concept in constant evolution, both from a scientific, professional and social point of view. Our university, due to the fact that it is public, has a greater responsibility in this sense”, he remarked.